Sino Biopharmaceutical

LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.

HanchorBio is a biotechnology research firm focused on developing innovative treatments for cancer. The company specializes in drug discovery that leverages tumor immunology, aiming to enhance the quality of life for cancer patients. By concentrating on cutting-edge research and development, HanchorBio seeks to revolutionize cancer treatment through its commitment to advancing therapeutic options.

Generon (Shanghai) Corporation Ltd. is a biotechnology company based in Shanghai, China, specializing in the discovery, development, and production of biomedicines for both domestic and international markets. The company primarily focuses on creating therapeutic recombinant proteins aimed at treating cancer, autoimmune, and inflammatory diseases. Its research and development center is situated in Zhang Jiang High-Tech Park, while its cGMP drug manufacturing facility is located in Beijing's Economic-Technological Development Area. Generon employs advanced technology platforms to innovate and produce biologic therapeutics, adhering to international quality standards and regulatory requirements. The company's mission centers on addressing unmet medical needs through innovative solutions in therapeutic biologics, emphasizing both innovation and quality in its drug development processes.

Medlinker operates as a social networking platform specifically designed for certified doctors, enabling them to connect with peers and access high-quality medical information. The platform facilitates knowledge sharing among healthcare professionals, allowing users to exchange experiences and insights. It offers various features, including medical quizzes, case mapping, and anonymous social circles, aimed at enhancing collaboration within the medical community. Additionally, Medlinker connects verified doctors with healthcare institutions, pharmaceutical companies, patients, and insurance firms, streamlining the process for patients to book medical appointments and submit inquiries to the medical community. Through these functionalities, Medlinker aims to improve the efficiency of healthcare interactions and support physicians in their professional development.

Treadwell Therapeutics Inc. is a clinical-stage oncology company focused on developing innovative therapeutics to meet unmet medical needs in cancer treatment. Founded in 2019 in New York, the company has a robust pipeline that includes several promising candidates, such as CFI-400945, a first-in-class PLK4 kinase inhibitor, and CFI-402257, a best-in-class TTK inhibitor. Additionally, Treadwell is advancing CFI-402411, an oral immunomodulatory kinase inhibitor targeting HPK1. The company also boasts a diverse pre-clinical pipeline featuring multiple biologic and next-generation TCR-based autologous cell therapy programs. With a commitment to exploiting cancer cell vulnerabilities, Treadwell Therapeutics aims to enhance recovery for patients through its innovative drug development efforts.

XtalPi Inc. is a pharmaceutical technology company that focuses on digital drug development solutions, leveraging quantum mechanics and artificial intelligence to enhance the efficiency of drug research and development. Founded in 2014 by a group of quantum physicists at MIT, the company has developed its Intelligent Digital Drug Discovery and Development (ID4) platform, which integrates advanced cloud computing algorithms to aid pharmaceutical firms in critical stages of drug R&D. XtalPi offers various tools, including XtalForc for visual force field calculations, XtalVision for crystal structure predictions, and Renova for platform support of its AI research initiatives. Its comprehensive services encompass crystal structure determination, solid-state testing, small molecule drug design, and collaborations in antibody and peptide research. Based in Cambridge, Massachusetts, with additional offices in China, XtalPi has established strategic partnerships with leading international pharmaceutical companies, demonstrating the broad applicability and recognition of its innovative technologies across the pharmaceutical value chain.

Softhale is a medical device company dedicated to developing Soft Mist Inhalation (SMI) devices designed for the effective delivery of pharmaceutical drugs to the lungs. The company's inhalable therapeutic devices utilize proprietary technical configurations to spray a propellant-free liquid formulation. This advanced delivery method allows medication to navigate the natural curve of the throat, offering patients the opportunity to inhale the medication more naturally. By ensuring that drugs reach deep into the lungs, Softhale aims to enhance respiratory treatments and provide relief for individuals suffering from chronic respiratory conditions.

Sinovac Life Sciences is a research-based company that conducts human vaccine research, development, manufacturing, and sales.

Akeso Biopharma, based in Zhongshan, China, operates as a contract research organization (CRO) specializing in the discovery and development of antibody and protein drugs. Founded in 2012, the company provides comprehensive CRO services to both domestic and international pharmaceutical clients, focusing on areas such as protein expression, antibody generation, assay development, and humanization. Akeso has developed an extensive biopharmaceutical research and development platform, with a robust product pipeline that includes over 30 drugs targeting cancers, autoimmune diseases, inflammation, and cardiovascular conditions. Among these, 17 drugs have progressed to clinical stages, including two first-in-class bi-specific antibody drugs. The company collaborates with various pharmaceutical firms to innovate and develop new drug candidates, establishing itself as a leader in the industry through its advanced facilities and expertise.

LifeBond Ltd. specializes in the development and manufacturing of absorbable bio-surgical medical devices aimed at enhancing tissue repair and improving patient recovery. The company's flagship product, LifeSeal, is designed to reinforce staple lines in bariatric and colorectal surgeries, helping to minimize complications such as leakage. Another key product, LifeMesh, is a self-fixating mesh intended for hernia repair, providing secure fixation and reducing post-surgical issues. LifeBond also focuses on the development of tissue adhesives and absorbable hemostats. Founded in 2006 and based in Caesarea, Israel, the company offers its innovative medical solutions across various international markets, including the United States, Europe, and China. Although LifeSeal and LifeMesh are currently investigational and not yet approved for sale, they represent significant advancements in addressing unmet surgical needs.